APO Research
Talk to an analyst

APO RESEARCH · REPORT

GABAA Receptor Agonists

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global GABAA Receptor Agonists Market Outlook and Growth Opportunities 2026

21 December 2025213 pages

Choose your research edition.

Industry ResearchGABAA Receptor Agonists Industry Research Report 2026148 pages · $2,950 USDIndustry Growth & TrendsGlobal GABAA Receptor Agonists Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal GABAA Receptor Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GABAA Receptor Agonists Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal GABAA Receptor Agonists Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global GABAA Receptor Agonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for GABAA Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GABAA Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GABAA Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the GABAA Receptor Agonists market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the GABAA Receptor Agonists market include Takeda, Teva, Sun Pharma, Shanghai Pharmaceuticals Holding, Sandoz, Sanofi, Novartis, Mylan and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global GABAA Receptor Agonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GABAA Receptor Agonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GABAA Receptor Agonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the GABAA Receptor Agonists market size, projected growth trends, production technologies, key applications, and end-use industries.

GABAA Receptor Agonists Segment by Company

Takeda

Teva

Sun Pharma

Shanghai Pharmaceuticals Holding

Sandoz

Sanofi

Novartis

Mylan

Roche

Pfizer

Huazhong Pharmaceutical

Sichuan HaiscoPharmaceuical

GSK

Fresenius Kabi

Changzhou Siyao Pharmaceutical

AstraZeneca

WG Critical Care

Viatris

Torrent Pharma

SAGE Therapeutics

Neurelis

Hikma

CHEPLAPHARM

Apotex

Akorn

GABAA Receptor Agonists Segment by Type

BZDs

Non-BZDs

GABAA Receptor Agonists Segment by Application

Epilepsy

Anxiety

Neuropathic Pain

Insomnia

Other

GABAA Receptor Agonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global GABAA Receptor Agonists status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions GABAA Receptor Agonists market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify GABAA Receptor Agonists significant trends, drivers, influence factors in global and regions.

6. To analyze GABAA Receptor Agonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GABAA Receptor Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GABAA Receptor Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GABAA Receptor Agonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the GABAA Receptor Agonists market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global GABAA Receptor Agonists industry.

Chapter 3: Detailed analysis of GABAA Receptor Agonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of GABAA Receptor Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of GABAA Receptor Agonists in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. GABAA Receptor Agonists Industry Trends Table 2. GABAA Receptor Agonists Industry Drivers Table 3. GABAA Receptor Agonists Industry Opportunities and Challenges Table 4. GABAA Receptor Agonists Industry Restraints Table 5. Global GABAA Receptor Agonists Revenue by Company (US$ Million) & (2021-2026) Table 6. Global GABAA Receptor Agonists Revenue Share by Company (2021-2026) Table 7. Global GABAA Receptor Agonists Sales Volume by Company (k units) & (2021-2026) Table 8. Global GABAA Receptor Agonists Sales Volume Share by Company (2021-2026) Table 9. Global GABAA Receptor Agonists Average Price (US$/unit) of Company (2021-2026) Table 10. Global GABAA Receptor Agonists Company Ranking, (2024-2026) & (USD Million) Table 11. Global GABAA Receptor Agonists Key Company Manufacturing Base & Headquarters Table 12. Global GABAA Receptor Agonists Company, Product Type & Application Table 13. Global GABAA Receptor Agonists Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global GABAA Receptor Agonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of BZDs Table 18. Significant Companies of Non-BZDs Table 19. Global GABAA Receptor Agonists Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global GABAA Receptor Agonists Sales Volume by Type (2021-2026) & (k units) Table 21. Global GABAA Receptor Agonists Sales Volume by Type (2027-2032) & (k units) Table 22. Global GABAA Receptor Agonists Sales Volume Share by Type (2021-2026) Table 23. Global GABAA Receptor Agonists Sales Volume Share by Type (2027-2032) Table 24. Global GABAA Receptor Agonists Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global GABAA Receptor Agonists Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global GABAA Receptor Agonists Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global GABAA Receptor Agonists Sales Value Share by Type (2021-2026) Table 28. Global GABAA Receptor Agonists Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Epilepsy Table 30. Significant Companies of Anxiety Table 31. Significant Companies of Neuropathic Pain Table 32. Significant Companies of Insomnia Table 33. Significant Companies of Other Table 34. Global GABAA Receptor Agonists Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global GABAA Receptor Agonists Sales Volume by Application (2021-2026) & (k units) Table 36. Global GABAA Receptor Agonists Sales Volume by Application (2027-2032) & (k units) Table 37. Global GABAA Receptor Agonists Sales Volume Share by Application (2021-2026) Table 38. Global GABAA Receptor Agonists Sales Volume Share by Application (2027-2032) Table 39. Global GABAA Receptor Agonists Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global GABAA Receptor Agonists Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global GABAA Receptor Agonists Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global GABAA Receptor Agonists Sales Value Share by Application (2021-2026) Table 43. Global GABAA Receptor Agonists Sales Value Share by Application (2027-2032) Table 44. Global GABAA Receptor Agonists Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global GABAA Receptor Agonists Sales by Region (2021-2026) & (k units) Table 46. Global GABAA Receptor Agonists Sales Market Share by Region (2021-2026) Table 47. Global GABAA Receptor Agonists Sales by Region (2027-2032) & (k units) Table 48. Global GABAA Receptor Agonists Sales Market Share by Region (2027-2032) Table 49. Global GABAA Receptor Agonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global GABAA Receptor Agonists Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global GABAA Receptor Agonists Sales Value Share by Region (2021-2026) Table 52. Global GABAA Receptor Agonists Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global GABAA Receptor Agonists Sales Value Share by Region (2027-2032) Table 54. Global GABAA Receptor Agonists Market Average Price (US$/unit) by Region (2021-2026) Table 55. Global GABAA Receptor Agonists Market Average Price (US$/unit) by Region (2027-2032) Table 56. Global GABAA Receptor Agonists Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global GABAA Receptor Agonists Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global GABAA Receptor Agonists Sales by Country (2021-2026) & (k units) Table 59. Global GABAA Receptor Agonists Sales Market Share by Country (2021-2026) Table 60. Global GABAA Receptor Agonists Sales by Country (2027-2032) & (k units) Table 61. Global GABAA Receptor Agonists Sales Market Share by Country (2027-2032) Table 62. Global GABAA Receptor Agonists Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global GABAA Receptor Agonists Sales Value Market Share by Country (2021-2026) Table 64. Global GABAA Receptor Agonists Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global GABAA Receptor Agonists Sales Value Market Share by Country (2027-2032) Table 66. Takeda Company Information Table 67. Takeda Business Overview Table 68. Takeda GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Takeda GABAA Receptor Agonists Product Portfolio Table 70. Takeda Recent Development Table 71. Teva Company Information Table 72. Teva Business Overview Table 73. Teva GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Teva GABAA Receptor Agonists Product Portfolio Table 75. Teva Recent Development Table 76. Sun Pharma Company Information Table 77. Sun Pharma Business Overview Table 78. Sun Pharma GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Sun Pharma GABAA Receptor Agonists Product Portfolio Table 80. Sun Pharma Recent Development Table 81. Shanghai Pharmaceuticals Holding Company Information Table 82. Shanghai Pharmaceuticals Holding Business Overview Table 83. Shanghai Pharmaceuticals Holding GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Shanghai Pharmaceuticals Holding GABAA Receptor Agonists Product Portfolio Table 85. Shanghai Pharmaceuticals Holding Recent Development Table 86. Sandoz Company Information Table 87. Sandoz Business Overview Table 88. Sandoz GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Sandoz GABAA Receptor Agonists Product Portfolio Table 90. Sandoz Recent Development Table 91. Sanofi Company Information Table 92. Sanofi Business Overview Table 93. Sanofi GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Sanofi GABAA Receptor Agonists Product Portfolio Table 95. Sanofi Recent Development Table 96. Novartis Company Information Table 97. Novartis Business Overview Table 98. Novartis GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Novartis GABAA Receptor Agonists Product Portfolio Table 100. Novartis Recent Development Table 101. Mylan Company Information Table 102. Mylan Business Overview Table 103. Mylan GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Mylan GABAA Receptor Agonists Product Portfolio Table 105. Mylan Recent Development Table 106. Roche Company Information Table 107. Roche Business Overview Table 108. Roche GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Roche GABAA Receptor Agonists Product Portfolio Table 110. Roche Recent Development Table 111. Pfizer Company Information Table 112. Pfizer Business Overview Table 113. Pfizer GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Pfizer GABAA Receptor Agonists Product Portfolio Table 115. Pfizer Recent Development Table 116. Huazhong Pharmaceutical Company Information Table 117. Huazhong Pharmaceutical Business Overview Table 118. Huazhong Pharmaceutical GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Huazhong Pharmaceutical GABAA Receptor Agonists Product Portfolio Table 120. Huazhong Pharmaceutical Recent Development Table 121. Sichuan HaiscoPharmaceuical Company Information Table 122. Sichuan HaiscoPharmaceuical Business Overview Table 123. Sichuan HaiscoPharmaceuical GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. Sichuan HaiscoPharmaceuical GABAA Receptor Agonists Product Portfolio Table 125. Sichuan HaiscoPharmaceuical Recent Development Table 126. GSK Company Information Table 127. GSK Business Overview Table 128. GSK GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. GSK GABAA Receptor Agonists Product Portfolio Table 130. GSK Recent Development Table 131. Fresenius Kabi Company Information Table 132. Fresenius Kabi Business Overview Table 133. Fresenius Kabi GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. Fresenius Kabi GABAA Receptor Agonists Product Portfolio Table 135. Fresenius Kabi Recent Development Table 136. Changzhou Siyao Pharmaceutical Company Information Table 137. Changzhou Siyao Pharmaceutical Business Overview Table 138. Changzhou Siyao Pharmaceutical GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 139. Changzhou Siyao Pharmaceutical GABAA Receptor Agonists Product Portfolio Table 140. Changzhou Siyao Pharmaceutical Recent Development Table 141. AstraZeneca Company Information Table 142. AstraZeneca Business Overview Table 143. AstraZeneca GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 144. AstraZeneca GABAA Receptor Agonists Product Portfolio Table 145. AstraZeneca Recent Development Table 146. WG Critical Care Company Information Table 147. WG Critical Care Business Overview Table 148. WG Critical Care GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 149. WG Critical Care GABAA Receptor Agonists Product Portfolio Table 150. WG Critical Care Recent Development Table 151. Viatris Company Information Table 152. Viatris Business Overview Table 153. Viatris GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 154. Viatris GABAA Receptor Agonists Product Portfolio Table 155. Viatris Recent Development Table 156. Torrent Pharma Company Information Table 157. Torrent Pharma Business Overview Table 158. Torrent Pharma GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 159. Torrent Pharma GABAA Receptor Agonists Product Portfolio Table 160. Torrent Pharma Recent Development Table 161. SAGE Therapeutics Company Information Table 162. SAGE Therapeutics Business Overview Table 163. SAGE Therapeutics GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 164. SAGE Therapeutics GABAA Receptor Agonists Product Portfolio Table 165. SAGE Therapeutics Recent Development Table 166. Neurelis Company Information Table 167. Neurelis Business Overview Table 168. Neurelis GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 169. Neurelis GABAA Receptor Agonists Product Portfolio Table 170. Neurelis Recent Development Table 171. Hikma Company Information Table 172. Hikma Business Overview Table 173. Hikma GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 174. Hikma GABAA Receptor Agonists Product Portfolio Table 175. Hikma Recent Development Table 176. CHEPLAPHARM Company Information Table 177. CHEPLAPHARM Business Overview Table 178. CHEPLAPHARM GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 179. CHEPLAPHARM GABAA Receptor Agonists Product Portfolio Table 180. CHEPLAPHARM Recent Development Table 181. Apotex Company Information Table 182. Apotex Business Overview Table 183. Apotex GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 184. Apotex GABAA Receptor Agonists Product Portfolio Table 185. Apotex Recent Development Table 186. Akorn Company Information Table 187. Akorn Business Overview Table 188. Akorn GABAA Receptor Agonists Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 189. Akorn GABAA Receptor Agonists Product Portfolio Table 190. Akorn Recent Development Table 191. Key Raw Materials Table 192. Raw Materials Key Suppliers Table 193. GABAA Receptor Agonists Distributors List Table 194. GABAA Receptor Agonists Customers List Table 195. Research Programs/Design for This Report Table 196. Authors List of This Report Table 197. Secondary Sources Table 198. Primary Sources List of Figures Figure 1. GABAA Receptor Agonists Product Image Figure 2. Global GABAA Receptor Agonists Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GABAA Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 4. Global GABAA Receptor Agonists Sales (2021-2032) & (k units) Figure 5. Global GABAA Receptor Agonists Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global GABAA Receptor Agonists Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. BZDs Image Figure 10. Non-BZDs Image Figure 11. Global GABAA Receptor Agonists Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global GABAA Receptor Agonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global GABAA Receptor Agonists Sales Volume Share by Type (2021-2032) Figure 14. Global GABAA Receptor Agonists Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global GABAA Receptor Agonists Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global GABAA Receptor Agonists Sales Value Share by Type (2021-2032) Figure 17. Epilepsy Image Figure 18. Anxiety Image Figure 19. Neuropathic Pain Image Figure 20. Insomnia Image Figure 21. Other Image Figure 22. Global GABAA Receptor Agonists Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global GABAA Receptor Agonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global GABAA Receptor Agonists Sales Volume Share by Application (2021-2032) Figure 25. Global GABAA Receptor Agonists Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global GABAA Receptor Agonists Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global GABAA Receptor Agonists Sales Value Share by Application (2021-2032) Figure 28. Global GABAA Receptor Agonists Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global GABAA Receptor Agonists Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global GABAA Receptor Agonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global GABAA Receptor Agonists Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America GABAA Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 33. North America GABAA Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe GABAA Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 35. Europe GABAA Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific GABAA Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific GABAA Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America GABAA Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 39. South America GABAA Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa GABAA Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa GABAA Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt GABAA Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. GABAA Receptor Agonists Value Chain Figure 127. Manufacturing Cost Structure Figure 128. GABAA Receptor Agonists Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • BZDs
  • Non-BZDs
Applications
  • Epilepsy
  • Anxiety
  • Neuropathic Pain
  • Insomnia
  • Other
Companies covered
  • Takeda
  • Teva
  • Sun Pharma
  • Shanghai Pharmaceuticals Holding
  • Sandoz
  • Sanofi
  • Novartis
  • Mylan
  • Roche
  • Pfizer
  • Huazhong Pharmaceutical
  • Sichuan HaiscoPharmaceuical
  • GSK
  • Fresenius Kabi
  • Changzhou Siyao Pharmaceutical
  • AstraZeneca
  • WG Critical Care
  • Viatris
  • Torrent Pharma
  • SAGE Therapeutics
  • Neurelis
  • Hikma
  • CHEPLAPHARM
  • Apotex
  • Akorn

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global GABAA Receptor Agonists Sales Value (2021-2032)
  4. 1.2.2 Global GABAA Receptor Agonists Sales Volume (2021-2032)
  5. 1.2.3 Global GABAA Receptor Agonists Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 GABAA Receptor Agonists Market Dynamics
  1. 2.1 GABAA Receptor Agonists Industry Trends
  2. 2.2 GABAA Receptor Agonists Industry Drivers
  3. 2.3 GABAA Receptor Agonists Industry Opportunities and Challenges
  4. 2.4 GABAA Receptor Agonists Industry Restraints
3 GABAA Receptor Agonists Market by Company
  1. 3.1 Global GABAA Receptor Agonists Company Revenue Ranking in 2025
  2. 3.2 Global GABAA Receptor Agonists Revenue by Company (2021-2026)
  3. 3.3 Global GABAA Receptor Agonists Sales Volume by Company (2021-2026)
  4. 3.4 Global GABAA Receptor Agonists Average Price by Company (2021-2026)
  5. 3.5 Global GABAA Receptor Agonists Company Ranking (2024-2026)
  6. 3.6 Global GABAA Receptor Agonists Company Manufacturing Base and Headquarters
  7. 3.7 Global GABAA Receptor Agonists Company Product Type and Application
  8. 3.8 Global GABAA Receptor Agonists Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global GABAA Receptor Agonists Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 GABAA Receptor Agonists Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 GABAA Receptor Agonists Market by Type
  1. 4.1 GABAA Receptor Agonists Type Introduction
  2. 4.1.1 BZDs
  3. 4.1.2 Non-BZDs
  4. 4.2 Global GABAA Receptor Agonists Sales Volume by Type
  5. 4.2.1 Global GABAA Receptor Agonists Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global GABAA Receptor Agonists Sales Volume by Type (2021-2032)
  7. 4.2.3 Global GABAA Receptor Agonists Sales Volume Share by Type (2021-2032)
  8. 4.3 Global GABAA Receptor Agonists Sales Value by Type
  9. 4.3.1 Global GABAA Receptor Agonists Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global GABAA Receptor Agonists Sales Value by Type (2021-2032)
  11. 4.3.3 Global GABAA Receptor Agonists Sales Value Share by Type (2021-2032)
5 GABAA Receptor Agonists Market by Application
  1. 5.1 GABAA Receptor Agonists Application Introduction
  2. 5.1.1 Epilepsy
  3. 5.1.2 Anxiety
  4. 5.1.3 Neuropathic Pain
  5. 5.1.4 Insomnia
  6. 5.1.5 Other
  7. 5.2 Global GABAA Receptor Agonists Sales Volume by Application
  8. 5.2.1 Global GABAA Receptor Agonists Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global GABAA Receptor Agonists Sales Volume by Application (2021-2032)
  10. 5.2.3 Global GABAA Receptor Agonists Sales Volume Share by Application (2021-2032)
  11. 5.3 Global GABAA Receptor Agonists Sales Value by Application
  12. 5.3.1 Global GABAA Receptor Agonists Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global GABAA Receptor Agonists Sales Value by Application (2021-2032)
  14. 5.3.3 Global GABAA Receptor Agonists Sales Value Share by Application (2021-2032)
6 GABAA Receptor Agonists Regional Sales and Value Analysis
  1. 6.1 Global GABAA Receptor Agonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global GABAA Receptor Agonists Sales by Region (2021-2032)
  3. 6.2.1 Global GABAA Receptor Agonists Sales by Region: 2021-2026
  4. 6.2.2 Global GABAA Receptor Agonists Sales by Region (2027-2032)
  5. 6.3 Global GABAA Receptor Agonists Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global GABAA Receptor Agonists Sales Value by Region (2021-2032)
  7. 6.4.1 Global GABAA Receptor Agonists Sales Value by Region: 2021-2026
  8. 6.4.2 Global GABAA Receptor Agonists Sales Value by Region (2027-2032)
  9. 6.5 Global GABAA Receptor Agonists Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America GABAA Receptor Agonists Sales Value (2021-2032)
  12. 6.6.2 North America GABAA Receptor Agonists Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe GABAA Receptor Agonists Sales Value (2021-2032)
  15. 6.7.2 Europe GABAA Receptor Agonists Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific GABAA Receptor Agonists Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific GABAA Receptor Agonists Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America GABAA Receptor Agonists Sales Value (2021-2032)
  21. 6.9.2 South America GABAA Receptor Agonists Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa GABAA Receptor Agonists Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa GABAA Receptor Agonists Sales Value Share by Country, 2025 VS 2032
7 GABAA Receptor Agonists Country-level Sales and Value Analysis
  1. 7.1 Global GABAA Receptor Agonists Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global GABAA Receptor Agonists Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global GABAA Receptor Agonists Sales by Country (2021-2032)
  4. 7.3.1 Global GABAA Receptor Agonists Sales by Country (2021-2026)
  5. 7.3.2 Global GABAA Receptor Agonists Sales by Country (2027-2032)
  6. 7.4 Global GABAA Receptor Agonists Sales Value by Country (2021-2032)
  7. 7.4.1 Global GABAA Receptor Agonists Sales Value by Country (2021-2026)
  8. 7.4.2 Global GABAA Receptor Agonists Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt GABAA Receptor Agonists Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt GABAA Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt GABAA Receptor Agonists Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda GABAA Receptor Agonists Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Teva GABAA Receptor Agonists Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Sun Pharma
  14. 8.3.1 Sun Pharma Company Information
  15. 8.3.2 Sun Pharma Business Overview
  16. 8.3.3 Sun Pharma GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sun Pharma GABAA Receptor Agonists Product Portfolio
  18. 8.3.5 Sun Pharma Recent Developments
  19. 8.4 Shanghai Pharmaceuticals Holding
  20. 8.4.1 Shanghai Pharmaceuticals Holding Company Information
  21. 8.4.2 Shanghai Pharmaceuticals Holding Business Overview
  22. 8.4.3 Shanghai Pharmaceuticals Holding GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Shanghai Pharmaceuticals Holding GABAA Receptor Agonists Product Portfolio
  24. 8.4.5 Shanghai Pharmaceuticals Holding Recent Developments
  25. 8.5 Sandoz
  26. 8.5.1 Sandoz Company Information
  27. 8.5.2 Sandoz Business Overview
  28. 8.5.3 Sandoz GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sandoz GABAA Receptor Agonists Product Portfolio
  30. 8.5.5 Sandoz Recent Developments
  31. 8.6 Sanofi
  32. 8.6.1 Sanofi Company Information
  33. 8.6.2 Sanofi Business Overview
  34. 8.6.3 Sanofi GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi GABAA Receptor Agonists Product Portfolio
  36. 8.6.5 Sanofi Recent Developments
  37. 8.7 Novartis
  38. 8.7.1 Novartis Company Information
  39. 8.7.2 Novartis Business Overview
  40. 8.7.3 Novartis GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Novartis GABAA Receptor Agonists Product Portfolio
  42. 8.7.5 Novartis Recent Developments
  43. 8.8 Mylan
  44. 8.8.1 Mylan Company Information
  45. 8.8.2 Mylan Business Overview
  46. 8.8.3 Mylan GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Mylan GABAA Receptor Agonists Product Portfolio
  48. 8.8.5 Mylan Recent Developments
  49. 8.9 Roche
  50. 8.9.1 Roche Company Information
  51. 8.9.2 Roche Business Overview
  52. 8.9.3 Roche GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Roche GABAA Receptor Agonists Product Portfolio
  54. 8.9.5 Roche Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer GABAA Receptor Agonists Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
  61. 8.11 Huazhong Pharmaceutical
  62. 8.11.1 Huazhong Pharmaceutical Company Information
  63. 8.11.2 Huazhong Pharmaceutical Business Overview
  64. 8.11.3 Huazhong Pharmaceutical GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Huazhong Pharmaceutical GABAA Receptor Agonists Product Portfolio
  66. 8.11.5 Huazhong Pharmaceutical Recent Developments
  67. 8.12 Sichuan HaiscoPharmaceuical
  68. 8.12.1 Sichuan HaiscoPharmaceuical Company Information
  69. 8.12.2 Sichuan HaiscoPharmaceuical Business Overview
  70. 8.12.3 Sichuan HaiscoPharmaceuical GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Sichuan HaiscoPharmaceuical GABAA Receptor Agonists Product Portfolio
  72. 8.12.5 Sichuan HaiscoPharmaceuical Recent Developments
  73. 8.13 GSK
  74. 8.13.1 GSK Company Information
  75. 8.13.2 GSK Business Overview
  76. 8.13.3 GSK GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 GSK GABAA Receptor Agonists Product Portfolio
  78. 8.13.5 GSK Recent Developments
  79. 8.14 Fresenius Kabi
  80. 8.14.1 Fresenius Kabi Company Information
  81. 8.14.2 Fresenius Kabi Business Overview
  82. 8.14.3 Fresenius Kabi GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Fresenius Kabi GABAA Receptor Agonists Product Portfolio
  84. 8.14.5 Fresenius Kabi Recent Developments
  85. 8.15 Changzhou Siyao Pharmaceutical
  86. 8.15.1 Changzhou Siyao Pharmaceutical Company Information
  87. 8.15.2 Changzhou Siyao Pharmaceutical Business Overview
  88. 8.15.3 Changzhou Siyao Pharmaceutical GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Changzhou Siyao Pharmaceutical GABAA Receptor Agonists Product Portfolio
  90. 8.15.5 Changzhou Siyao Pharmaceutical Recent Developments
  91. 8.16 AstraZeneca
  92. 8.16.1 AstraZeneca Company Information
  93. 8.16.2 AstraZeneca Business Overview
  94. 8.16.3 AstraZeneca GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 AstraZeneca GABAA Receptor Agonists Product Portfolio
  96. 8.16.5 AstraZeneca Recent Developments
  97. 8.17 WG Critical Care
  98. 8.17.1 WG Critical Care Company Information
  99. 8.17.2 WG Critical Care Business Overview
  100. 8.17.3 WG Critical Care GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 WG Critical Care GABAA Receptor Agonists Product Portfolio
  102. 8.17.5 WG Critical Care Recent Developments
  103. 8.18 Viatris
  104. 8.18.1 Viatris Company Information
  105. 8.18.2 Viatris Business Overview
  106. 8.18.3 Viatris GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Viatris GABAA Receptor Agonists Product Portfolio
  108. 8.18.5 Viatris Recent Developments
  109. 8.19 Torrent Pharma
  110. 8.19.1 Torrent Pharma Company Information
  111. 8.19.2 Torrent Pharma Business Overview
  112. 8.19.3 Torrent Pharma GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Torrent Pharma GABAA Receptor Agonists Product Portfolio
  114. 8.19.5 Torrent Pharma Recent Developments
  115. 8.20 SAGE Therapeutics
  116. 8.20.1 SAGE Therapeutics Company Information
  117. 8.20.2 SAGE Therapeutics Business Overview
  118. 8.20.3 SAGE Therapeutics GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 SAGE Therapeutics GABAA Receptor Agonists Product Portfolio
  120. 8.20.5 SAGE Therapeutics Recent Developments
  121. 8.21 Neurelis
  122. 8.21.1 Neurelis Company Information
  123. 8.21.2 Neurelis Business Overview
  124. 8.21.3 Neurelis GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Neurelis GABAA Receptor Agonists Product Portfolio
  126. 8.21.5 Neurelis Recent Developments
  127. 8.22 Hikma
  128. 8.22.1 Hikma Company Information
  129. 8.22.2 Hikma Business Overview
  130. 8.22.3 Hikma GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Hikma GABAA Receptor Agonists Product Portfolio
  132. 8.22.5 Hikma Recent Developments
  133. 8.23 CHEPLAPHARM
  134. 8.23.1 CHEPLAPHARM Company Information
  135. 8.23.2 CHEPLAPHARM Business Overview
  136. 8.23.3 CHEPLAPHARM GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 CHEPLAPHARM GABAA Receptor Agonists Product Portfolio
  138. 8.23.5 CHEPLAPHARM Recent Developments
  139. 8.24 Apotex
  140. 8.24.1 Apotex Company Information
  141. 8.24.2 Apotex Business Overview
  142. 8.24.3 Apotex GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Apotex GABAA Receptor Agonists Product Portfolio
  144. 8.24.5 Apotex Recent Developments
  145. 8.25 Akorn
  146. 8.25.1 Akorn Company Information
  147. 8.25.2 Akorn Business Overview
  148. 8.25.3 Akorn GABAA Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  149. 8.25.4 Akorn GABAA Receptor Agonists Product Portfolio
  150. 8.25.5 Akorn Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 GABAA Receptor Agonists Value Chain Analysis
  2. 9.1.1 GABAA Receptor Agonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 GABAA Receptor Agonists Sales Mode & Process
  6. 9.2 GABAA Receptor Agonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 GABAA Receptor Agonists Distributors
  9. 9.2.3 GABAA Receptor Agonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst